Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (14)

2024

  1. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology

2022

  1. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 635-645

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2018

  1. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38

2017

  1. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

2016

  1. Lung cancer in women with a family history of cancer: The Spanish female-specific database WORLD07

    Anticancer Research, Vol. 36, Núm. 12, pp. 6647-6653

  2. Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: The Spanish oncologic genitourinary group (SOGUG) SPAZO study

    Annals of Oncology, Vol. 27, Núm. 4, pp. 706-711

2010

  1. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

    Journal of Translational Medicine, Vol. 8

2009

  1. Assessing the value of preoperative chemotherapy in early-stage non-small cell lung cancer: mature data and prognostic factors analysis of a Phase III randomized trial of surgery alone vs preoperative Paclitaxel/Carboplatin (PC) vs postoperative PC. Final NATCH data. A Spanish Lung Cancer Group Trial

    EJC SUPPLEMENTS

  2. Recommendations from the Spanish oncology genitourinary group for the treatment of metastatic renal cancer

    Cancer Chemotherapy and Pharmacology

2002

  1. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

    Cancer, Vol. 95, Núm. 4, pp. 751-757

2000

  1. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer

    European Journal of Cancer, Vol. 36, Núm. SUPPL. 2, pp. 17-25

  2. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium

    Journal of Clinical Oncology, Vol. 18, Núm. 18, pp. 3247-3255

1998

  1. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: Comparison of two phase II trials

    Clinical Cancer Research, Vol. 4, Núm. 11, pp. 2723-2728